论文部分内容阅读
[目的]观察伊班膦酸联合内分泌治疗前列腺癌骨转移患者的疗效及安全性。[方法]16例前列腺癌骨转移患者应用伊班膦酸4mg,每月1次,同时行去势治疗及抗雄激素治疗。[结果]骨转移灶变化:好转6例,稳定8例,进展2例。止痛效果:显效9例,有效5例,无效2例,总有效率为87.5%。活动能力:有效11例,无变化4例,进展1例。不良反应多为0～1度,经对症治疗后均很快缓解,无严重不良反应发生。[结论]伊班膦酸联合内分泌治疗前列腺癌骨转移临床疗效确切,能减少骨相关不良事件发生,提高患者生活质量,耐受性好,不良反应少。
[Objective] To observe the efficacy and safety of ibandronic acid combined with endocrine in the treatment of patients with prostate cancer with bone metastasis. [Method] 16 cases of patients with prostate cancer with bone metastasis were treated with ibandronic acid 4mg once a month, and treated with castration therapy and anti-androgen therapy at the same time. [Results] The changes of bone metastases: improved in 6 cases, stable in 8 cases, progress in 2 cases. Analgesic effect: markedly effective in 9 cases, effective in 5 cases, ineffective in 2 cases, the total effective rate was 87.5%. Activities: Effective in 11 cases, no change in 4 cases, 1 case of progress. Adverse reactions were mostly 0 to 1 degree, after symptomatic treatment were quickly relieved, no serious adverse reactions. [Conclusion] Ibandronic acid combined with endocrine treatment of prostate cancer bone metastases clinical efficacy is exact, can reduce the incidence of bone-related adverse events, improve patient quality of life, good tolerance, fewer adverse reactions.